Coronary stenting is a key component of percutaneous coronary intervention (PCI), even with the advantage of lower restenosis with drug-eluting stents. The overall safer profile of the bare-metal stents keeps them important. There is little research on the improvements in bare-metal stent design platforms and their biocompatibility impact. One study was undertaken in a porcine coronary model of the biocompatibility of various bare metal stents, and included the transitioning design (Nexgen) novel cobalt chromium stent. At 28 days histomorphometric analysis after sacrifice showed major distinctions in mid stent neointimal thickness (0.18 + 0.08 mm for group A ( NexGen) vs 0.33 + 0.13 mm for group B (Driver, Medtronic) and C (Duraflex, Avantec) , p=0.03), preferring thinner strut CoCr stents as benefits were found with the thinner strut CoCr stents on mid stent neointimal hyperplasia at 90 days. The study offers in-vivo demonstration.